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Interaction of yeast Rvs167 and Pho85 cyclin-dependent kinase
complexes may link the cell cycle to the actin cytoskeleton
Jinhwa Lee, Karen Colwill, Vicky Aneliunas*, Christine Tennyson, Lynda Moore,
Yuen Ho and Brenda Andrews
Background: PHO85 encodes the catalytic subunit of a cyclin-dependent
kinase (Cdk) in budding yeast and functions in phosphate and glycogen
metabolism. Pho85 associated with the G1 cyclins Pcl1 and Pcl2 is also
required for cell cycle progression in the absence of the Cdc28 cyclins Cln1
and Cln2. Loss of Pcl1, Pcl2 and related Pho85 cyclins results in budding
defects, suggesting that Pcl–Pho85 complexes function in cell morphogenesis
early in the cell cycle; their precise role is not clear, however.
Results: To identify targets for Pcl–Pho85 kinases, we performed yeast 
two-hybrid interaction screens using Pcl2 and the related cyclin Pcl9. We
identified RVS167, a gene involved in endocytosis, organization of the actin
cytoskeleton, and cell survival after starvation. Like rvs167∆ mutants, pho85
mutants or strains deleted for the Pcl1,2-type Pho85 cyclins showed
abnormal cell morphology on starvation, sensitivity to salt, random budding in
diploids, and defects in endocytosis and in the actin cytoskeleton.
Overexpression of Rvs167 in wild-type cells caused morphological
abnormalities and growth arrest at high temperatures; these phenotypes 
were exacerbated by deleting PHO85. Rvs167 has a Src homology 3 (SH3)
domain and five potential Pho85 phosphorylation sites; recombinant 
Rvs167 was phosphorylated by the Pcl2–Pho85 kinase in vitro. 
Maximal phosphorylation of Rvs167 in vivo required Pho85 and the 
Pcl1,2-type cyclins. 
Conclusions: Rvs167 interacts with Pho85 cyclins and is implicated as a
target of Pho85 kinases in vivo. Our results identify a connection between
Cdks and the actin cytoskeleton; interaction of Rvs167 and Pcl–Pho85 Cdks
might contribute to actin cytoskeleton regulation in response to stresses such
as starvation.
Background
In the budding yeast Saccharomyces cerevisiae, commitment
to the cell cycle occurs in late G1 phase once cells reach a
critical cell size; this commitment phase is known as
‘Start’ and is analogous to the restriction point in mam-
malian cells [1]. Cell cycle transitions, including Start, are
governed by members of a highly conserved family of pro-
teins called cyclin-dependent kinases (Cdks). As their
name implies, Cdk activation requires binding of a posi-
tive regulatory subunit called a cyclin. Like Cdks, cyclins
form a large family of related proteins that share sequence
homology in a region called the ‘cyclin box’ that is
required for Cdk interaction [2]. The Cdc28 protein is the
major cell cycle regulatory Cdk in budding yeast. At Start,
Cdc28 associates with the G1 cyclins, Cln1, Cln2 and
Cln3, to promote cell cycle commitment. After Start, pro-
gression through subsequent phases of the cell cycle
(S-phase and mitosis) depends on activation of Cdc28 by
other cyclins called Clbs [1].
Recent work, largely in yeast, has shown that Cdk com-
plexes not only promote cell cycle transitions but also
function to regulate gene expression and other cellular
processes [3]. PHO85 encodes a multifunctional Cdk in
budding yeast that is 51% identical to Cdc28 [4]. Although
PHO85 is not an essential gene, pho85 mutant strains show
a broad spectrum of phenotypes, indicating many cellular
roles for Pho85 Cdk complexes. Consistent with the mul-
tifunctional nature of Pho85, 10 genes encoding known or
putative Pho85 cyclins (Pcls) have been identified [5].
The Pho85 cyclins have been divided into two subfamilies
based on sequence similarity within the cyclin-box region
[3,5]. The Pho80 subfamily is composed of Pho80, Pcl6,
Pcl7, Pcl8 and Pcl10. The in vivo substrates of three Pho80
subfamily kinases have been identified. When complexed
with Pho80, Pho85 controls expression of the major acid
phosphatase gene, PHO5, by phosphorylating Pho4, a
basic-helix-loop-helix transcription factor [6]. Two other
members of the Pho80 subfamily, Pcl8 and Pcl10, convey
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Pho85 kinase activity towards Gsy2, the major isoform of
glycogen synthase, both in vivo and in vitro [7].
The five remaining Pho85 cyclins are related to Pcl1 and
Pcl2, and form a second subfamily known as the Pcl1,2
subfamily [5]. The biological substrates for these cyclin
complexes are not known, but a number of observations
suggest a role for Pcl1,2-type kinases in regulating early
cell cycle events. First, although strains deleted for PCL1
and PCL2 are viable, Pcl1,2–Pho85 kinases are required
for G1 phase progression in the absence of the Cdc28
cyclins CLN1 and CLN2 suggesting a role for Pcl1,2–Pho85
kinases at Start [8,9]. Second, expression of three
members of the Pcl1,2 subfamily is cell cycle regulated,
with peak expression in early or late G1 phase [5,10,11].
Third, yeast strains lacking the entire Pcl1,2 subfamily
show morphological and budding defects that include
elongated buds, connected chains of cells and a random
budding phenotype in diploids [5,11]. These observations
suggest that Pcl1,2–Pho85 kinases function to regulate
aspects of cell morphogenesis and budding early in the
cell cycle, a contribution that becomes essential when
other G1 regulators are compromised.
Proper cell morphogenesis and bud emergence requires a
marked polarization of growth and secretion and is depen-
dent on the dynamic function of the actin cytoskeleton,
which undergoes rearrangements throughout the cell cycle
[12]. The spectrum of phenotypes seen in actin mutants has
revealed functions for the actin cytoskeleton in polarized
cell growth and secretion, budding and bud site selection,
endocytosis, sporulation and cytokinesis [12]. Two related
genes, RVS161 and RVS167, function in actin cytoskeleton
regulation and were first identified in a screen for mutations
that caused reduced viability on starvation (rvs mutants
[13]). Deletion of RVS161 or RVS167 leads to a similar spec-
trum of phenotypes, suggesting a role for the RVS genes in
regulation of the actin cytoskeleton in response to varying
nutrients or stress. The phenotypes associated with dele-
tion of the RVS genes include the following: first, loss of via-
bility and unusual cell morphology in poor growth media or
salt-containing media; second, delocalized actin distribution
under suboptimal growth conditions [13–15]; third, abnor-
mal (random) budding in diploids [13,14]; fourth, a defect
in endocytosis [16]; and fifth, poor sporulation [17]. Other
observations suggest that Rvs161 and Rvs167 bind actin or
actin-associated proteins. For example, Rvs167 interacts
with actin in a yeast two-hybrid interaction assay and binds
the same subset of actin mutants as profilin, a regulator of
actin assembly [18]. The interaction of Rvs167 with actin
may be indirect as Rvs167 also binds directly to the actin-
binding protein Abp1 in vitro [19]. 
Rvs167 is composed of three predicted protein–protein
interaction domains. First, Rvs167 contains a carboxy-ter-
minal Src homology 3 (SH3) domain that is required for
both the interaction with actin in the two-hybrid assay
and for binding to Abp1 in vitro [18,19]. Second, in
Rvs167 the SH3 domain is preceded by a region rich in
glycine, proline and alanine called the GPA domain;
similar regions are found in other actin-associated pro-
teins such as myosin I and Abp1 [13]. Third, the amino-
terminal region of Rvs167 and the entire Rvs161 protein
has been dubbed the RVS or BAR (Bin1–Amphiphysin
RVS) domain [13,15,20-22]. Within the BAR/RVS region
are sequences predicted to form two coiled-coil struc-
tures [23]. Thus, the predicted structure of Rvs167 sug-
gests that it can interact with multiple proteins through
distinct domains.
In this paper, we report the results of genetic and bio-
chemical experiments that implicate Rvs167 as a target of
Pcl1,2–Pho85 Cdk complexes in vivo. We identify Rvs167
as a protein that can interact with Pcl2 and related cyclins
both in vivo and in vitro. We propose that interaction of
Rvs167 and Pcl–Pho85 Cdks contributes to actin
cytoskeleton regulation early in the cell cycle. 
Results
Interaction of Pcl2 and Pcl9 with Rvs167 in a two-hybrid
assay
To identify targets or regulators of Pcl–Pho85 kinase com-
plexes, we used yeast two-hybrid screens to search for pro-
teins that interacted with the related Pho85 cyclins Pcl2
and Pcl9 [5]. The two-hybrid screen with Pcl2 has been
previously described and led to the identification of Pho85
as the Cdk partner for Pcl2 [8]. For the Pcl9 screen, library
transformants were screened using the yeast strains
described by James et al. [24]. We identified multiple
independent isolates of Rvs167 from both genomic and
cDNA libraries tagged with the Gal4 activation domain
(AD) in the Pcl2 and Pcl9 screens. Quantitative β-galac-
tosidase assays showed that the interaction of Pcl2 with
the largest Rvs167–AD fusion identified in the screen
resulted in close to 400-fold stimulation of reporter gene
expression (pAD-RVS167∆11, Table 1). The fusion
protein encoded by this RVS167–AD isolate lacked the
first amino-terminal 11 amino acids of Rvs167. Activation
of the reporter gene was also seen with the Gal4 DNA-
binding domain (DB) fusion protein DB–Pcl9 and
AD–Rvs167∆11 (Table 1). In this case, activation of the
reporter gene was not as pronounced as that seen with
Pcl2. This result may reflect the fact that the DB–Pcl9
fusion protein was expressed from a crippled promoter
[24]. Because Rvs167 binds actin and Apb1 via the
carboxy-terminal SH3 domain [18,19], we tested interac-
tion of an Rvs167–AD fusion lacking the SH3 domain
with Pcl2 and Pcl9 in the two-hybrid system (Table 1).
The SH3 domain of Rvs167 was not required for interac-
tion of Pcl2 or Pcl9 with Rvs167 indicating that binding of
the cyclins to Rvs167 requires a region distinct from that
required for interaction with actin and Abp1.
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Association of Rvs167 and Pcl2 in vitro and in yeast lysates
To corroborate the Rvs167–Pcl2 two-hybrid interaction, we
used two assays to test for complex formation in vitro. First,
in vitro translated Pcl2 and Pho85 were tested for binding
to glutathione-S-transferase (GST)–Rvs167 ligands in a
batch affinity chromatography assay (Figure 1a and data not
shown). When Pcl2 was incubated with a full-length
GST–Rvs167 ligand, over 50% of the Pcl2 was specifically
retained on the resin (Figure 1a, lanes 3–6). An Rvs167
ligand lacking the carboxy-terminal SH3 domain also
bound Pcl2 effectively (Figure 1a, lanes 7,8). By contrast,
Pho85 failed to bind to Rvs167 above background in the
batch affinity chromatography assay (data not shown). 
We used a second biochemical assay to confirm an associa-
tion between Pcl2 and Rvs167. Immunoprecipitation of
Pcl2 from yeast extracts with polyclonal Pcl2 antiserum [8]
followed by immunoblotting with Rvs167 antibodies
revealed an association between Pcl2 and Rvs167
(Figure 1b, lanes 2,4). The Pcl2–Rvs167 interaction was
not detected in extracts from pcl2∆ strains (Figure 1b,
lane 6) confirming the specificity of the Pcl2–Rvs167
interaction. Consistent with our batch affinity chromato-
graph assay, we were also able to detect coimmunoprecipi-
tation of Pcl2 and Rvs167 in extracts from a pho85 deletion
strain (data not shown). Reproducible detection of the
association between Pcl2 and Rvs167 in yeast extracts
required overproduction of Rvs167 (Figure 1b); this is
probably due to the small amount of Pcl2 that can be
immunoprecipitated from yeast extracts and the sensitiv-
ity of the immunoprecipitation–western assay. We were
unable to use an Rvs167 immunoprecipitation reaction to
look at associated Pcl2 protein because Pcl2 is not rou-
tinely visible on western blots from yeast extracts using
our antiserum. In any case, three independent assays (two-
hybrid, coimmunoprecipitation and GST pull-down) all
show interaction between Rvs167 and Pcl2. The assays
indicate that Pcl2 interacts directly with Rvs167 and that
the interaction is independent of the Rvs167 SH3 domain. 
The rvs167, pho85 and pcl mutant strains show similar
phenotypes
To begin to assess the relevance of the Pcl–Rvs167 inter-
action in vivo, we examined the phenotypes of pho85 and
pcl mutant strains in light of the known defects of rvs167
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Table 1
Interaction of Pcl2 and Pcl9 with Rvs167 in the two-hybrid
system.
Plasmid pAS1* pAS1-PCL2* Fold increase
in activation†
pAD 0.15 0.53 3.5
pAD-RVS167∆11 0.16 63 394
pAD-RVS167∆SH3 0.13 81 623
Plasmid pGBD* pGBD-PCL9* Fold increase
in activation†
pAD 0.16 0.10 0.63
pAD-RVS167∆11 0.43 2.12 4.9
pAD-RVS167∆SH3 0.35 1.52 4.3
Yeast strains transformed with a plasmid expressing a Pcl2 (pAS1-
PCL2) or Pcl9 (pGBD-PCL9) fusion to the Gal4-DB or expressing the
Gal4-DB alone (pAS1 or pGBD) were mated with strains transformed
with Gal4-AD (pAD) constructs. Plasmids pAD-RVS167∆11 and pAD-
RVS167∆SH3 express AD–Rvs167 fusion proteins. Data are the
average of two to three independent transformants. *Values are given
as Miller Units of β-galactosidase, as defined [5]. †Relative to the pAS1
or pGBD control.
Figure 1
Binding of Pcl2 to GST–Rvs167 and GST–Rvs167∆SH3 in vitro.
(a) Pcl2 was translated in vitro and incubated with either GST,
GST–Rvs167 or GST–Rvs167∆SH3 immobilized on glutathione
beads. U indicates the unbound fraction (the supernatant) and B
indicates the fraction bound to the beads. The estimated concentration
of ligand (µg/µl) is indicated. The unbound and bound fractions
represent the entire binding reactions. (b) Coimmunoprecipitation of
Pcl2 and Rvs167 from yeast extracts. Western blot analysis using
Rvs167 antiserum was performed on Pcl2 immunoprecipitates from
yeast strains transformed with a control plasmid (vector, V) or a
plasmid overexpressing RVS167 (Rvs167) as indicated. Strains were
grown for 18–22 h in galactose-containing medium to induce RVS167
expression prior to harvesting the cells for extract preparation. The top
panel shows the Rvs167 immunoblot of Pcl2 immunoprecipitates
(IP–western) and the bottom panel an Rvs167 western blot of the
same yeast extracts used in the immunoprecipitations (western; 10 µg
yeast extract per lane). Lanes 1,2, wild-type strain (WT, BY261)
transformed with vector or pGAL-RVS167; lanes 3,4, rvs167∆ strain
(BY508) transformed with vector or pGAL-RVS167; lanes 5,6, pcl2∆
strain (BY344) transformed with vector or pGAL-RVS167. The
position of migration of Rvs167 is indicated on the right.
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mutants. We previously reported that, like rvs167 mutants
[13,15], pho85 and pcl mutant strains show a random
budding phenotype in diploid cells [11]. We next assessed
pho85 and pcl mutants for an endocytotic defect, another
mutant phenotype seen in rvs167 mutants under standard
growth conditions [16]. To determine if loss of Pho85 or
Pcl1,2-type cyclins abolished endocytosis, we assayed
fluid-phase endocytosis of lucifer yellow in pho85 and pcl1
pcl2 pcl5 pcl9 clg1 (quintiple pcl deletion; quint∆) mutant
strains. We chose to assay mutant phenotypes in strains
lacking all Pcl1,2 subfamily members because our previ-
ous studies indicate some functional redundancy among
the PCL genes [5,11]. The pho85, pcl and rvs167 mutant
cells all had a vacuolar compartment of at least wild-type
size as viewed with Nomarski optics (Figure 2). However,
fluorescence microscopy revealed that, like rvs167
mutants, both pho85 and the pcl mutants were defective
for lucifer yellow accumulation in the vacuole (Figure 2).
Phenotypes for pho85 and pcl mutant cells were also evident
in certain stress conditions that compromise the growth of
rvs167 mutants. We used a plating assay to compare the
growth of wild-type, rvs167, pho85 and pcl mutant cells on
medium containing 6% sodium chloride (Figure 3). Wild-
type, pcl2∆ and pcl2∆ pcl9∆ strains were able to form
colonies on the high salt medium (Figure 3, compare YPDS
versus YPD). By contrast, a strain lacking Pho85 or the
Pcl1,2-type cyclins (Figure 3, quint∆) failed to grow on the
salt-containing medium. The salt sensitivity seen in these
mutant strains was comparable to that seen in the isogenic
strain deleted for RVS167. We also assayed the same series
of strains for cell viability and morphology after starvation in
carbon-limiting medium. As previously reported for rvs167
mutants [13], we found that pho85∆ and pcl mutant cells
were of various sizes and showed an unusual morphology
upon starvation with many large, swollen cells visible in the
culture (data not shown). In the pho85 and pcl mutants, a
significant reduction in cell viability after starvation was also
seen (data not shown). In our strain background, however,
we saw only a slight decrease in cell viability after starvation
for the rvs167 mutant, in contrast to previous reports [13]
(data not shown). We presume that this discrepancy reflects
differences in strain background. In summary, our pheno-
typic analysis revealed new phenotypes for strains lacking
Pcl1,2-type Pho85 kinases that are shared with rvs167
mutants and many other mutants with defects in actin func-
tion. Our genetic evidence suggests that the Rvs167–Pcl2
interaction that we detected in two-hybrid and biochemical
assays reflects a common function for Rvs167 and the
Pcl1,2–Pho85 Cdks in vivo.
Actin organization defects in pho85 and pcl mutant strains
Because the phenotypic defects shared between rvs167,
pho85 and pcl mutants are often associated with defects in
actin cytoskeletal function, we asked whether pho85 and pcl
mutants showed a loss of actin organization as previously
reported for rvs167 mutants [13–15]. In yeast, the actin
cytoskeleton consists of cortical patches and cables and the
distribution of these structures varies through the cell cycle
[12]. Cortical actin patches concentrate in the bud during
early bud emergence and, in general, are concentrated at
sites of surface growth. Figure 4 shows examples of actin
localization in budded cells in wild-type, rvs167∆, pho85∆
and pcl mutant strains. Strains were grown in rich medium
or in salt-containing medium, and the actin cytoskeleton
was visualized with rhodamine-conjugated phalloidin. The
salt concentration we chose for this experiment (3% NaCl)
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Figure 2
Assay of endocytosis in cultures of wild-type, rvs167∆, pho85∆ and
pcl1∆pcl2∆clg1∆pcl5∆pcl9∆ cells. Fluid-phase endocytosis was
assayed using lucifer yellow (LY) on the following haploid strains: wild-
type (WT, BY261), rvs167∆ (BY508), pho85∆ (BY391) and quint∆
(pcl1∆pcl2∆clg1∆pcl5∆pcl9∆, BY714). Lucifer yellow accumulation
was visualized with fluorescein isothiocyanate (FITC) fluorescence
optics and photographed at a magnification of 630× using an imaging
system (see Materials and methods). Photographs of the same field of
cells viewed with Nomarski optics (differential interference contrast)
are shown to the right.
WT
rvs167∆
pho85∆
quint∆
Current Biology   
LY Nomarski
1314 Current Biology, Vol 8 No 24
was previously shown to exacerbate the actin delocalization
phenotype of rvs167 and rvs161 mutants [13,15] but still
allowed continued growth of the strains. To assess actin
cytoskeletal polarity, we looked at the distribution of actin
patches in budded cells in the culture and scored cells as
polarized (bright staining patches in daughter cell, very
little staining in mother cell), partially depolarized (some
concentration of actin patches in daughter cell, but obvious
staining in mother cell) or depolarized (random distribution
of actin patches between mother and daughter cells). As
expected, most wild-type cells showed polarized cortical
actin patches in the growing bud even in salt-containing
medium (96% of small-to-medium budded cells with local-
ized actin patches, n = 50, Figure 4). As previously reported
[13], however, a significant fraction of rvs167∆ cells showed
delocalized actin patches with a random distribution of
patches between mother and bud (40% of cells with par-
tially delocalized actin patches, 60% delocalized in budded
cells, n = 50). The actin delocalization in the rvs167∆ cells
was more pronounced following salt treatment (100% delo-
calized actin patches in budded cells, n = 50). In rich
medium, we observed that 86% of budding pho85 mutant
cells had partial actin delocalization with visible actin
patches in the mother cells but with some brighter actin
staining in the growing bud (n = 50). The remainder of the
budding pho85 mutant cells in the culture showed com-
pletely delocalized actin patches. The strain lacking all
Pcl1,2-type cyclins (quint∆, Figure 4) showed delocalized
actin patches in virtually all cells in the population although
some concentration of actin was seen at the tips of many of
the abnormal buds in this strain. Like the rvs167 mutant,
the actin organization defect of the pho85 and pcl mutant
cells was more pronounced in medium containing salt. In
some cells, the morphological abnormalities associated with
loss of Pho85 or the Pcl1,2-type cyclins made assessment of
the actin phenotype difficult. Nonetheless, it was clear
that, like rvs167 mutants, pho85 and pcl mutant cells show
abnormalities in the actin cytoskeleton.
Phenotypic consequences of Rvs167 overexpression
To develop strains for studying protein complexes contain-
ing Rvs167, we constructed a yeast expression vector in
which Rvs167 was overexpressed from the inducible galac-
tose promoter (pGAL-RVS167). Western blot analysis
using anti-Rvs167 antiserum showed that Rvs167 was sig-
nificantly overexpressed in transformants expressing
RVS167 from pGAL-RVS167 (for example, see later). To
determine if overexpression of Rvs167 caused a cell-
growth phenotype, we plated haploid cells transformed
with pGAL-RVS167 on non-inducing medium (dextrose)
or on medium containing galactose to induce high level
expression of RVS167 (Figure 5a). Overexpression of
Figure 3
Effects of salt stress on the growth of rvs167∆, pho85∆ and pcl∆
strains. Growth of wild-type (WT), rvs167, pho85, pcl2 and multiple
pcl strains on medium containing sodium chloride. Serial dilutions of
log phase cultures of the following strains were plated on YPD or
YPDS (6% NaCl) media: wild-type (BY263), rvs167∆ (BY508),
pho85∆ (BY391), pcl2∆ (BY344), pcl2∆ pcl9∆ (BY697) and quint∆
(pcl1∆pcl2∆clg1∆pcl5∆pcl9∆, BY714). Plates were incubated at 30°C
for 5 days and photographed. 
YPD YPDS (6%)
Current Biology   
WT
rvs167∆
pho85∆
pcl2∆
pcl2∆pcl9∆
quint∆
Figure 4
Actin localization in wild-type, rvs167∆, pho85∆ and pcl∆ cells. Cells
were grown in rich medium (YPD) or in rich medium with 3% NaCl
(YPDS), fixed, and the actin stained using rhodamine-conjugated
phalloidin as described in Materials and methods. Examples of actin
localization in the following diploid cells are shown: wild-type (WT,
BY264), rvs167∆ (BY561), pho85∆ (BY868) and
pcl1∆pcl2∆clg1∆pcl5∆pcl9∆ (quint∆, BY730). Stained actin was
visualized by fluorescence microscopy at 600× magnification. The
fluorescence image (rhodamine) appears to the right of a photograph
of the same field of cells visualized with Nomarski optics.
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Rvs167 caused a slow-growth phenotype and abnormal cell
morphology when cells were grown at 30°C and caused
growth arrest at 37°C (Figure 5a,c). Interestingly, the slow-
growth phenotype caused by Rvs167 overexpression was
exacerbated by loss of Pho85 (Figure 5b) or the Pcl1,2-type
cyclins (data not shown). This type of genetic interaction
has been termed ‘synthetic dosage lethality’ and has been
used to identify genes encoding functionally interacting
proteins [25]. Our observations are consistent with a model
in which Rvs167 participates in a protein complex or regu-
latory process that is disrupted by overexpression of
Rvs167; the perturbation of Rvs167 function in this context
is enhanced by the absence of Pcl1,2–Pho85 kinases. 
Phosphorylation of Rvs167 by Pcl–Pho85 kinases
The biochemical and genetic interactions that we
detected between Pcl kinases and Rvs167 suggested that
Rvs167 may be a substrate of Pcl–Pho85 kinases. We
tested this possibility by preparing purified recombinant
Rvs167 protein to use as a substrate in Pcl–Pho85 kinase
assays. The Pho80/Pho85-dependent phosphorylation
sites on the Pho4 transcription factor have been mapped
[26] and define a consensus for phosphorylation (S/T-P-X-
hydrophobic; in single-letter amino acid code where X is
any amino acid) whereas a slightly different target site for
the Pcl10–Pho85 kinase has been defined on the Gsy2
protein (S/T-P-X-D; [7]). Based on these consensus
sequences, Rvs167 contains several potential Pho85 phos-
phorylation sites clustered near or in the SH3 domain in
the carboxyl terminus of the protein (S379, S390, S407,
T412 and T454). 
Truncation derivatives of Rvs167 containing one or more
of these putative Pho85 phosphorylation sites were puri-
fied as GST fusions from bacterial cells and incubated
with Pcl2–Pho85 in the presence of radiolabelled ATP. All
Rvs167 protein derivatives were specifically phosphory-
lated by Pcl2–Pho85 in the in vitro kinase reaction while
GST alone was not phosphorylated in the reaction
(Figure 6). We were also able to detect phosphorylation of
the purified full-length GST–Rvs167 fusion protein that
we used in our affinity chromatography experiments in
Figure 1 (data not shown). We were able to recover only
very small amounts of full-length protein from the glu-
tathione–sepharose beads, however, and the signal
obtained in the kinase assays with the truncated deriva-
tives of Rvs167 was much stronger. We conclude that
Rvs167 is a substrate for Pcl2–Pho85 kinase in vitro.
Next, we asked whether phosphorylation of Rvs167 was
dependent on Pcl–Pho85 kinases in vivo. We assayed
phosphorylation of Rvs167 in two ways. First, when
Rvs167 immunoprecipitates (Figures 7a,8a) or crude yeast
extracts (Figure 8b) were resolved by SDS–PAGE, multi-
ple isoforms were detected by immunoblotting with
Rvs167 antiserum. Phosphatase treatment of the extract
resulted in loss of the slower migrating (upper) species
and an increase in the fastest migrating isoform (Figure 7a,
lane 3); the presence of phosphatase inhibitors in the
phosphatase reaction prevented this conversion
(Figure 7a, lane 2). Immunoprecipitation of Rvs167 from
extracts of yeast cells grown in the presence of
[32P]orthophosphate confirmed that Rvs167 was a phos-
phoprotein in vivo (Figure 7b). When overproduced, phos-
phorylated Rvs167 was easily detected in extracts from
orthophosphate-labelled cells (Figure 7b, lane 2); Rvs167
was also labelled in vivo when expressed at endogenous
levels, however (Figure 7b, lanes 1,3; pGAL-RVS167
expresses endogenous levels of Rvs167 when cells are
grown in dextrose).
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Figure 5
Effect of RVS167 overexpression in wild-type and pho85∆ strains.
Yeast strains transformed with vector (V) or a plasmid expressing
RVS167 from the GAL promoter were grown in synthetic dextrose or
synthetic galactose medium lacking leucine (Leu–) for plasmid
selection. (a) Wild-type cells (WT, BY261) transformed with vector or
the RVS167 plasmid were grown in dextrose to log phase, serially
diluted and plated on dextrose or galactose medium. The plates were
incubated at 30°C or 37°C until individual colonies were visible and
then photographed. For all strains, 104, 103, 102 and 10 cells were
plated in spots from left to right on the plates as shown. (b) A pho85∆
strain (BY867) was transformed with a control vector or
pGAL-RVS167. Serial dilutions of exponentially growing cultures were
spotted onto selective medium as described for (a). (c) Morphology of
diploid wild-type cells overexpressing RVS167. Wild-type cells
(BY262) transformed with either vector or pGAL-RVS167 were grown
to mid-log phase in galactose medium to induce expression of
RVS167. Cells were cultured for 5 h and viewed at 400× magnification
with Nomarski optics and photographed.
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Importantly, we found that phosphorylation of Rvs167 was
partially dependent on Pcl–Pho85 kinases in vivo. Rvs167
immunoblots of extracts or Rvs167 immunoprecipitates
from pho85∆ or pcl∆ strains showed that the phosphory-
lated isoforms of Rvs167 were reduced in the extracts from
the pcl or pho85 mutant strains (Figure 8a, compare
lanes 2–4). The slower migrating phosphoforms of Rvs167
sometimes appeared to migrate as a single band (as in
Figure 8a) but they often resolved into multiple species
showing that Rvs167 is phosphorylated on multiple sites.
For example, the multiple Rvs167 isoforms were clearly
visible in the immunoblots of log-phase extracts from wild-
type cells shown in Figure 8b (lane 1). Again, some, but
not all, of the phosphoforms were absent in extracts from
the multiple pcl mutant strain (Figure 8b, lane 5). Thus,
the reproducible reduction in Rvs167 phosphorylation that
we see in the pho85 and pcl mutant strains suggests that
phosphorylation at certain sites on the Rvs167 protein is
dependent on Pcl–Pho85 kinases in vivo. Our data clearly
suggest that other kinases also phosphorylate Rvs167.
As a further test of the dependence of Rvs167 phosphory-
lation on Pcl–Pho85 kinases in vivo, we examined Rvs167
phosphoforms in cells treated with α factor, a pheromone
Figure 6
Kinase assays with Pcl2 immunoprecipitates and Rvs167 substrates.
(a) Analysis of substrates used in kinase assays. One nanomole each of
purified GST–GPASH3 (a GST fusion to the GPA and SH3 domains of
Rvs167; lane 2), GST–GPA (lane 3), GST–SH3 (lane 4) and GST
(lane 5) were resolved by SDS–PAGE and visualized by Coomassie
blue staining. Lane 1 shows molecular size markers (M). All proteins
were purified from bacteria as described in Materials and methods.
(b) Pcl2–Pho85 complexes were immunoprecipitated from wild-type
(WT, BY261) or pcl2∆ (∆, BY344) strains using Pcl2 antiserum, and
1 nmol of the purified substrates shown in (a) was added: lanes 1,2,
GST–GPASH3; lanes 3,4, GST–GPA; lanes 5,6, GST–SH3; and lanes
7,8, GST. The migration position of each phosphorylated protein is
indicated by an asterisk beside the phosphorylated band on the gel.
The bracket and asterisk to the right of the gel mark the migration
position of coimmunoprecipitated Pcl2–Pho85 substrates [8]. 
(c) A schematic diagram showing the GPA and SH3 regions of Rvs167
and the putative Pho85 phosphorylation sites.
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Figure 7
Analysis of Rvs167 phosphoforms in vivo. (a) Cell extracts were
prepared from exponentially growing cultures of rvs167∆ (lane 1;
BY508) or wild-type (WT, lanes 2,3; BY261) strains. Rvs167 was
immunoprecipitated from cell extracts with affinity-purified anti-Rvs167
antiserum coupled to protein-A–Sepharose beads. The
immunoprecipitates were treated with 1 unit of calf intestinal
phosphatase (CIP) or with CIP in the presence of the phosphatase
inhibitor β-glycerophosphate (CIP + Inh). The immunoprecipitates were
resolved by SDS–PAGE, transferred to nitrocellulose and probed with
Rvs167 antiserum. IgG indicates the immunoglobulin G. (b) Rvs167
was labelled in vivo with [32P]orthophosphate and immunoprecipitated
from extracts of rvs167∆ cells (BY508) transformed with pGAL-
RVS167. Cells were grown in either dextrose (Dex; lanes 1,3) to repress
expression of RVS167 from the plasmid or galactose (Gal; lanes 2,4) to
induce RVS167 expression. Lanes 1,2 show an autoradiogram of the
Rvs167 immunoprecipitates, and lanes 3,4 show a western blot of the
same immunoprecipitates probed with anti-Rvs167 antiserum.
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that arrests cells at Start in preparation for mating. PCL2
transcript is induced rapidly in response to α factor, and
the associated Pcl2–Pho85 kinase activity also increases
during pheromone-mediated arrest [8]. Interestingly, we
found that Rvs167 was hyperphosphorylated in
pheromone-treated cell extracts (Figure 8b, lane 2). In a
pcl2∆ strain, the pheromone-dependent phosphorylation
was clearly reduced; some Rvs167 isoforms appeared to be
entirely Pcl2 dependent whereas others were maintained
in the pcl2∆ strain (Figure 8b, compare lanes 2 and 4).
Equal loading of cell extracts in this experiment was
ensured by quantitation of total protein in the extract and
a control immunoblot with an unrelated antiserum (anti-
Swi6, data not shown). No further reduction in the
α-factor-dependent Rvs167 phosphorylation was seen
when other Pcl1,2-type cyclins were also absent (quint∆;
Figure 8b, compare lanes 4 and 6). Thus, in contrast to the
situation in log-phase cells, other Pcl1,2-type cyclins were
unable to compensate for the absence of Pcl2 to phospho-
rylate Rvs167 in response to α-factor treatment. Rather,
the Pcl2-dependent induction of Rvs167 phosphorylation
in response to pheromone mirrored the induction of
Pcl2–Pho85 kinase [8]. Together, our in vivo and in vitro
data implicate Rvs167 as a substrate of Pcl–Pho85 kinases. 
Discussion
Pho85 encodes a multifunctional protein kinase that has
roles in regulating cell metabolism and division [3]. Pho85
is thought to carry out its many functions through associa-
tion with different Pho85 cyclins, or Pcls, of which ten are
known [5]. Genetic studies and gene expression analysis
have implicated Pho85 Cdk complexes in regulating early
cell cycle progression and cell morphogenesis when com-
plexed with members of the Pcl1,2-type cyclins [5,11]. In
this paper, we describe several new phenotypes of pho85
and pcl1,2-subfamily mutants that suggest a defect in actin
cytoskeleton function. In two-hybrid screens with Pcl2
and Pcl9, we identified RVS167, a gene previously shown
to be important for endocytosis, cell survival after starva-
tion, and actin cytoskeletal organization. We found that
Rvs167 was phosphorylated by Pcl2–Pho85 kinase in vitro
and that phosphorylation of Rvs167 was partially depen-
dent on Pcl–Pho85 kinases in vivo. Together, these data
suggest that regulation of Rvs167 by Pcl–Pho85 Cdks may
contribute to control of actin cytoskeleton rearrangements
early in the cell cycle. 
Interaction of Pcl1,2-type cyclins and Rvs167
Two-hybrid, coimmunoprecipitation and GST–Rvs167
binding assays showed that Pcl2 interacts with Rvs167.
Therefore, we are confident in our assignment of Pcl2 as
an Rvs167-binding protein. We also identified Rvs167 in a
screen for proteins that interact with Pcl9, the Pho85
cyclin most closely related to Pcl2 (64% identical [5,11]).
In fact, all members of the Pcl1,2 subfamily can interact
with GST–Rvs167 in vitro whereas other Pho85 cyclins
(the Pho80 subfamily) interact only poorly with Rvs167 in
the same assay (L.M., unpublished observations). 
Consistent with the ability of all Pcl1,2-type cyclins to
bind Rvs167 in at least one in vitro assay, we found genetic
redundancy amongst the Pcl1,2-type cyclins in their dele-
tion phenotypes in vivo. Several of the phenotypes that we
discovered, such as salt sensitivity and defective endocy-
tosis, were most pronounced when all five members of the
Pcl1,2 subfamily were absent. Despite this genetic redun-
dancy for certain phenotypes, two observations indicate
that Pcl1,2-type cyclins are likely to have functional dis-
tinctions. First, Pcl1 and Pcl2 are required for viability in
the absence of the Cdc28 cyclins, Cln1 and Cln2 [8]. In
this particular genetic circumstance, other Pcl1,2-type
cyclins cannot substitute for Pcl1 and Pcl2 to allow
passage through G1 phase. In the case of Pcl9, which is
highly related to Pcl2, the failure to provide the essential
Pcl–Pho85 function in the absence of CLN1 and CLN2
might simply reflect the fact that PCL9 expression is at
Figure 8
Analysis of Rvs167 phosphoforms in wild-type, pho85∆ and pcl∆
strains. (a) Cell extracts were prepared from exponentially growing
cultures of rvs167∆ (BY508), wild-type (WT, BY261), pho85∆
(BY391) and quint∆ mutant (pcl1∆ pcl2∆ clg1∆ pcl5∆ pcl9∆, BY714)
strains. Immunoprecipitations were performed using equal amounts of
cell extract with anti-Rvs167 antiserum coupled to protein-A–
Sepharose beads. IgG indicates the immunoglobulin G. (b) Analysis of
Rvs167 isoforms in extracts from α-factor-treated cells. Extracts were
prepared from log phase or α-factor-arrested cell cultures. Anti-
Rvs167 western blot analysis of 10 µg of the following cell extracts is
shown: lane 1, log-phase wild-type strain; lane 2, α-factor-arrested
wild-type strain; lane 3, log phase pcl2∆ strain (BY344); lane 4,
α-factor-arrested pcl2∆ strain; lane 5, log-phase quint∆ strain
(BY714); lane 6, α-factor-arrested quint∆ strain. 
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maximal levels in early G1 phase [10,11]. As such, there
may be insufficient Pcl9–Pho85 complexes in late G1
phase to compensate for the absence of Pcl1 and Pcl2.
Second, in α-factor-arrested cells, we observed phosphory-
lation of Rvs167 that was dependent on Pcl2 but indepen-
dent of the other Pcl1,2-type cyclins. The dependence of
Rvs167 phosphorylation on Pcl2 during α-factor treatment
is likely to reflect the induction of PCL2 expression and
Pcl2–Pho85 kinase activity that occurs after pheromone
treatment [8]. As neither pcl2 nor rvs167 mutants have a
significant defect in the pheromone response, the biologi-
cal importance of Rvs167 hyperphosphorylation in
response to α factor is as yet unclear. In contrast to PCL2,
levels of PCL1 transcript decrease rapidly in response to
pheromone and PCL9 transcript levels also decrease
because of the timing of PCL9 expression [10,11]. We
suggest that the highly related G1-specific Pho85 cyclins,
Pcl1, Pcl2 and Pcl9, normally function in aspects of actin
regulation distinct from the more distantly related cyclins
(Clg1, Pcl5). Our data indicate that one aspect of this func-
tion involves the phosphorylation and regulation of
Rvs167. The dramatic morphological abnormalities associ-
ated with deletion of the Pcl1,2-type cyclins also suggest
that other substrates of Pho85 may also be involved in reg-
ulating cell morphology and the cytoskeleton. A test of
these ideas will require the development of kinase assays
for other Pcl1,2-type cyclins and the identification of other
targets of Pho85 kinases related to actin regulation and G1
progression in addition to Rvs167.
Rvs167 and Pcl–Pho85 kinases as components of protein
complexes regulating the actin cytoskeleton
We have accumulated genetic and biochemical results that
implicate Rvs167 as a target of Pcl1,2-type Pho85 kinases
and suggest a role for these Cdks in actin cytoskeleton reg-
ulation early in the cell cycle. What properties of Rvs167
might be regulated by Pho85 kinases? Phosphorylation of
Rvs167 by Pcl–Pho85 kinases might influence the interac-
tion of Rvs167 with other actin regulatory proteins. Specifi-
cally, a number of genetic and some biochemical
observations suggest that Rvs167 interacts with the actin-
binding protein Abp1 to regulate the actin cytoskeleton.
First, as noted in the Background, the SH3 domain of
Rvs167 is required for interaction with actin in a two-
hybrid assay [18]. Abp1 binds directly to the Rvs167 SH3
domain in vitro, however, suggesting that the interaction of
Rvs167 with actin may be indirect [19]. Second, deletion of
either RVS167 or ABP1 does not cause a dramatic growth
defect in standard conditions, and an rvs167 abp1 double
mutant shows no additional phenotypes. The rvs167 and
abp1 mutants, however, show the same profile of synthetic
lethal interactions with genes encoding other cytoskeletal
components including SRV2, SLA1, SLA2/END4 and SAC6
[19]. Third, overexpression of ABP1 [19,27] or RVS167
(this paper) causes morphological abnormalities and tem-
perature sensitivity. In the case of ABP1 overexpression,
the growth defect is suppressed by deletion of RVS167 sug-
gesting that misregulation of Rvs167 may be contributing
to the Abp1 overexpression phenotype [19]. 
Together, these data suggest that Rvs167 and Abp1 may
form a complex that functions to control the actin
cytoskeleton in response to various stresses, a function
that becomes essential in the absence of other cytoskeletal
proteins. The potential Pho85 phosphorylation sites in
Rvs167 all cluster near or in the SH3 domain (Figure 6c).
One putative Pho85 phosphorylation site, T454, resides
within the SH3 domain and is probably phosphorylated in
vitro by Pcl2–Pho85 kinase (Figure 6b). Alignment of the
SH3 domain of Rvs167 with SH3 domains from other pro-
teins shows that T454 lies within the so-called ‘n-Src loop’
that is involved in ligand binding in other SH3 domains
(Alan Davidson, personal communication) [28]. Phospho-
rylation of T454 by Pcl2–Pho85, and perhaps other sites
amino terminal to the SH3 domain, might regulate the
interaction of Abp1 with the SH3 domain of Rvs167.
In addition to binding Abp1, Rvs167 has been implicated
in interactions with other actin regulatory proteins. As
noted above, a significant function of the SH3 domain of
Rvs167 is probably to interact with Abp1. Other proteins
may also interact with the SH3 domain or other regions of
Rvs167. For example, a protein interaction involving
Rvs167 has been suggested by two-hybrid experiments
showing an interaction between Rvs167 and a central
coiled-coil domain in the actin regulatory protein
Sla2/End4 [29]. Interestingly, the coiled-coil domain of
the Sla2/End4 protein has an endocytic function that is
redundant with Abp1 and the Abp1-binding protein, Srv2
[29]. These observations prompted the hypothesis that a
common function of End4, Abp1 and Srv2 involves direct
or indirect interaction with Rvs167 [29]. 
Like Sla2/End4, Rvs167 is predicted to contain alpha-
helical coiled-coil structures within its amino-terminal
BAR/RVS region [15]. Two-hybrid and coimmunoprecipi-
tation experiments have shown that Rvs161, which is com-
posed only of a BAR region, can interact with Rvs167 [23].
Recent work suggests that Rvs161 is not always com-
plexed with Rvs167, however. Alleles of RVS161 have
been identified that are specifically defective in either
endocytosis or cell fusion [30]. The organization of the
actin cytoskeleton was not impaired in the cell fusion
mutants, showing that the function of Rvs161 in cell fusion
is independent of its role in actin regulation. As Rvs167 is
not required for cell fusion [30], it is unlikely to participate
in protein complexes with Rvs161 during mating. In any
case, phosphorylation of Rvs167 by Pcl–Pho85 may serve
to influence the association of Rvs167 with Abp1, Rvs161,
Sla2/End4 or other proteins either by direct regulation of
the interaction between the proteins or by influencing
their subcellular localization. As not all phosphorylation on
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Rvs167 is dependent on Pho85, other kinases may also
influence the formation of protein complexes involving
Rvs167. A test of this model will require an analysis of the
phenotypic consequences of mutating the phosphorylation
sites on Rvs167 and study of the subcellular localization of
Rvs167 and Pcls. It is important to note that deletion
studies have shown that derivatives of Rvs167 lacking the
SH3 domain are able to complement several rvs167
mutant phenotypes ([15], K.C., unpublished observations).
As our work and other studies suggest an important role for
the Rvs167 SH3 domain, we suspect that the subtle phe-
notypic consequences of deleting the SH3 domain of
Rvs167 reflect the overlapping functions of components of
the actin cytoskeleton.
Conservation of regulatory pathways involving Rvs- and
Pho85-like proteins
Our studies of Pho85 and Rvs167 might define a conserved
regulatory pathway involving regulation of cell morphogen-
esis and polarity by Cdks. Two mammalian homologues of
Rvs167, called amphiphysin I and amphiphysin II, have
been identified [31]. Like Rvs167, amphiphysins contain
an amino-terminal BAR/RVS domain and a carboxy-termi-
nal SH3 domain. Amphiphysins are involved in endocyto-
sis during synaptic vesicle recycling at presynaptic nerve
terminals and bind to proteins required for endocytosis
such as dynamin and clathrin [31]. Recently, amphiphysin
I was shown to colocalize with actin and dynamin in the
growth cones of developing neurons. Also, depletion of
amphiphysin I using antisense oligonucleotides leads to
growth-cone collapse, implicating amphiphysin I in inter-
actions with actin or actin-binding proteins to promote
cytoskeletal polarization during neuronal outgrowth [32].
Amphiphysin I is dephosphorylated after depolarization of
nerve terminals and phosphorylation of amphiphysin
affects its interaction with proteins involved in clathrin-
mediated endocytosis [33–36]. Thus, like the Rvs proteins
in yeast, amphiphysins appear to be regulated by phospho-
rylation and are involved in controlling endocytosis and
actin cytoskeletal function.
Interestingly, Pho85 is most similar to mammalian Cdk5
which, like Pho85, has important non-mitotic roles. Cdk5
associates with a neuronal-specific activator, p35, and has
been proposed to play a regulatory role in cytoskeletal
dynamics and neuronal differentiation [37]. Like
amphiphysin, Cdk5 colocalizes with actin in the growth
cones of developing neurons and is involved in neural out-
growth [38]. Whether amphiphysins are direct or indirect
targets of Cdk5 remains to be determined. 
Conclusions
Rvs167 associates with Pho85 cyclins in two-hybrid assays
and in yeast extracts. The phenotypes associated with
deletion of pho85 or the pcl1,2 subfamily overlap with those
of rvs167 mutants, consistent with a common role for
Pcl1,2–Pho85 kinases and Rvs167 in actin cytoskeleton
regulation. Rvs167 is a phosphoprotein and a subset of
Rvs167 phosphoforms are dependent on Pho85 and Pcl1,2-
type cyclins in vivo. Some phosphoforms of Rvs167 are
induced, in a Pcl2-dependent manner, when cells are
arrested in G1 phase by pheromone treatment. Rvs167
contains five potential Pho85 phosphorylation sites in or
near the carboxy-terminal SH3 domain and we suggest that
Pho85-dependent phosphorylation of Rvs167 may serve to
regulate protein interactions involving the SH3 domain of
Rvs167. Although neither Rvs167 nor Pcl–Pho85 kinases
are essential for yeast growth, this and other work suggests
that these proteins function to regulate the actin cytoskele-
tal machinery. The emerging picture places Pcl–Pho85
kinases and Rvs167 in protein complexes that serve to
coordinate actin assembly, endocytosis and the cellular
response to environmental stress. 
Materials and methods
Media and yeast strain manipulations
Yeast strains are listed in the Supplementary material published with
this paper on the internet. Standard rich medium (YEP) containing 2%
glucose (YPD) or 2% galactose (YPG) and supplemented minimal
medium (SD or SG) were used. To make YPDS, NaCl was added to
YPD medium to a final concentration of 6% weight : volume. For [32P]
labeling experiments, inorganic phosphate was removed from YPD or
YPG by precipitation with Mg2+ at high pH. Yeast strain BY867
(pho85∆TRP1) was constructed using a PCR-based strategy that
allowed targeted gene replacement of PHO85 coding sequences with
the TRP1 gene (details of strain construction available on request).
Gene disruptions were confirmed by Southern blot analysis.
Plasmids
The pAS1-PCL2 plasmid (pBA668) that was used in the two-hybrid
screen has been described [8]. The plasmid expressing a Gal4-DB
fusion to PCL9 was constructed by cloning a BamHI fragment contain-
ing the PCL9 coding sequence [5] into the BamHI site of the vector
pGBD-C2 [24]. Plasmid AD-RVS167∆11 (pBA706) was isolated as a
positive interactor in our Pcl2 two-hybrid screen (this paper and [8]).
This construct encodes a Gal4-AD–Rvs167 fusion protein lacking the
first 11 amino-terminal amino acids of Rvs167. Plasmid AD-
RVS167∆SH3 (pBA822), which expresses a Gal4-AD–Rvs167 fusion
protein lacking the first 11 and the last 40 amino acids of Rvs167, was
generated by subcloning a blunted XhoI–NaeI fragment from pBA706
into the SmaI site of pACTII. Plasmid pBA837, which carries the full-
length RVS167 gene, was created by PCR amplification from genomic
DNA using primers with BglII linkers. The resulting PCR product was
cleaved with BglII and cloned into a BglII site of a modified pRS316
vector. Plasmid pGAL-RVS167 was constructed by cloning the BglII
fragment of RVS167 from pBA837 into BamHI site of Yep55a. In
plasmid pGAL-RVS167, Rvs167 is expressed from the GAL10 pro-
moter and has an additional eight amino acids (MTARSTDL) encoded
by linker sequences fused to its amino terminus. Vectors for expressing
deletion derivatives of Rvs167 in bacteria were constructed. Plasmid
pGst-RVS167∆SH3 (pBA894) encodes a GST–Rvs167 fusion
protein lacking the 38 carboxy-terminal amino acids of Rvs167 and
was constructed by cloning a BglII–NaeI fragment from pBA837 into
the BamHI–SmaI sites of pGEX-1. GST fusions to various subdomains
of Rvs167 were constructed by PCR amplification from pBA819 or
pBA837 templates, cloning into an intermediate vector (pBA89) and
finally subcloning into pGEX-1. Constructs encoding GST fusions to
the SH3 domain of Rvs167 (codons 428–482), the GPA domain of
Rvs167 (codons 282–427) and the GPA and SH3 domains of Rvs167
(codons 282–482) were constructed in this manner (details of plasmid
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construction are available on request). All PCR products were
sequenced to confirm their integrity. The GST–Rvs167 fusion protein
used for antibody production was expressed from plasmid pBA713
which was constructed by ligating a BamHI–BglII fragment from
plasmid pBA706 (AD-RVS167-∆11) into the BamHI site of pGEX-1.
Plasmid pBA713 encodes a fusion of Rvs167 lacking the first 29
amino-terminal amino acids fused to GST (GST–Rvs167-∆29). The
plasmids used as templates for in vitro transcription–translation of
Pho85 and His–Pcl2 have been described [8].
Two-hybrid assay
The two-hybrid screen that identified RVS167 using pAS1-PCL2 has
been described [8]. The two-hybrid screen with PCL9 was performed by
transformation of yeast strain PJ69-4A [24] with plasmid pGBD-PCL9.
This strain was then transformed with the yeast genomic two-hybrid
libraries Y2HL-C1, Y2HL-C2 and Y2HL-C3 [24]. A total of 1× 106
colonies from each library were screened for growth on selective media
as described [24]. Plasmids from positive clones were then isolated and
sequenced. For liquid β-galactosidase assays, yeast (Y153; see Supple-
mentary material) bearing a plasmid expressing a Gal4-DB–Pcl2 fusion
(pAS1-PCL2), a Gal4-DB–Pcl9 fusion (pGBD-PCL9), or the Gal4-DB
alone (pAS1, [39] or pGBD [24]) were mated to strain Y187 (see Sup-
plementary material) transformed with plasmids encoding Rvs167
fusions with the Gal4-AD or the Gal4-AD alone (pAD in Table 1). Liquid
β-galactosidase assays were performed as described [5]. 
Batch affinity chromatography assay
GST–Rvs167 fusion proteins for ligands in GST pull-down experiments
were isolated from mid-log-phase (1 l) cultures of Escherichia coli NB42
(a lon– strain) harboring the appropriate expression plasmid. Cells were
harvested, lysed, and the fusion protein bound to glutathione–sepharose
4B (Pharmacia) as described [5]. For in vitro binding assays, 5 µl Pcl2
translation reaction was incubated with 12.5 µl beads bound with the
indicated concentrations of GST, GST–Rvs167, or GST–Rvs167∆SH3,
in a total volume of 50 µl buffer D [8] at room temperature for 2 h. The
beads were pelleted by gentle centrifugation for 2 min and the 50µl
supernatant was collected and boiled in an equal volume of 2× SDS
sample buffer (unbound fraction, U). The beads were washed four times
with 1 ml of RIPA-500 (50 mM Tris-HCl pH 8, 0.1% SDS, 500 mM
NaCl, 1% Triton-X-100) buffer, resuspended in 50 µl buffer D plus 50 µl
2 × SDS sample buffer and boiled (bound fraction, B). The unbound and
bound fractions were analyzed by 10% SDS–PAGE.
Purification of substrates for in vitro kinase assays
GST and GST–Rvs167-SH3 were prepared by inducing 0.3–1.5 l mid-
log cultures of E. coli strain DH5α, harboring either plasmid pGEX-1 or
pBA1052, with 0.4 mM IPTG for 3 h at 30°C. Cells were harvested and
lysed and fusion proteins bound to glutathione–sepharose as recom-
mended (Pharmacia). Proteins were eluted in elution buffer B (20 mM
Hepes pH 8, 0.1 mM PMSF, 0.1 mM DTT with the first elution step using
20 mM glutathione, and the second step using 40 mM glutathione). Frac-
tions containing protein were pooled and dialyzed into 20 mM Hepes pH
8, 10% glycerol, 0.1 mM DTT, 0.1 mM PMSF. GST–Rvs167-GPA and
GST–Rvs167-GPA-SH3 were purified using a similar protocol. Prepara-
tion of yeast extracts for kinase assays and the Pcl2 immunoprecipita-
tion–kinase assay were performed as described [8], except that 4 mg of
cell extract were used to immunoprecipitate the Pcl2–Pho85 complex.
Antibody preparation
Production of anti-Pcl2 antisera has been described [8]. Antibody to
Rvs167 was prepared against the antigen GST–Rvs167∆29 encoded
by pBA713 (see above). GST–Rvs167∆29 was purified from inclusion
bodies, eluted from SDS gels and used to immunize rabbits (Faculty of
Medicine, University of Toronto). Antiserum was affinity purified as
described [8].
Protein immunoprecipitation and western blotting
To prepare crude extracts for immunoprecipitation or western blotting,
yeast cells were grown to log phase, harvested, washed and quickly
frozen in liquid N2 or on dry ice. Cell extracts were prepared by vortex-
ing cells with glass beads in lysis buffer (0.1% NP-40, 1 mM DTT,
250 mM NaCl, 5 mM EDTA, 50 mM Tris pH 7.5, 1 µM PMSF, 1 µg/ml
pepstatin, 1 µg/ml leupeptin, 10 µg/ml soybean trypsin inhibitor,
10 µg/ml N tosyl-L-phenylalanine chloromethyl ketone). For immunopre-
cipitation, either the affinity purified anti-Pcl2 antibody or anti-Rvs167
antibody were coupled to protein-A–Sepharose beads (Sigma) and
added to cell extracts (100 µg total protein in 200 µl lysis buffer for
Rvs167 immunoprecipitation; 2.5–3.0 mg total protein for Pcl2
immunoprecipitation). After incubation for 2 h at 4°C, the beads were
washed four times with RIPA buffer (50 mM Tris, pH 8, 0.1% SDS,
0.5% deoxycholate, 150 mM NaCl, 1% Triton X-100) or lysis buffer
(Pcl2 immunoprecipitation experiment) and boiled in SDS sample
buffer. Proteins were separated by 8 or 10% SDS–PAGE and trans-
ferred to nitrocellulose using a semi-dry transfer apparatus (BioRad).
Immunoblots were probed with a 1:2000 dilution of affinity-purified
Rvs167 antibody, and subsequently with a 1:10 000 dilution of goat-
anti-rabbit Ig–peroxidase (BioRad). Proteins were visualized using
enhanced chemiluminescence (Renaissance detection system, NEN).
To examine Rvs167 isoforms in pheromone-arrested cells, strains were
grown in YPD to early log phase. Where specified, α-factor (Vetrogen)
was added to 5 µM and the culture was incubated at 30°C for 140 min
(95% arrest) before harvesting. Cells were resuspended in an equal
volume of 2 × SDS sample buffer without dye (125 mM Tris HCl
pH 6.8, 20% glycerol, 4.6% SDS, 10% β-mercaptoethanol) and lysed
by agitation in the presence of glass beads. The extracts were boiled
for 3 min before centrifugation in a microfuge for 5 min. The protein
concentration in the extracts was quantitated by Bradford assay
(BioRad) and 10 µg of each extract was resolved by 7.5%
SDS–PAGE. Rvs167 was detected as described above for the log-
phase extracts. 
In vivo labeling and phosphatase treatment
Cells were grown to an OD600 of 0.5 in SD Leu– or SG Leu– medium.
Cells were washed twice then resuspended and incubated for 30 min
in YPD-Pi or YPG-Pi medium. [32P]orthophosphate was added to
1 mCi per 5 ml culture and cells were labeled for 2 h before harvesting
and processing for immunoprecipitation. Samples were resolved by
10% SDS–PAGE and visualized by autoradiography. For phosphatase
experiments, Rvs167 immunoprecipitates from yeast extracts were
washed three times with RIPA buffer and twice with phosphatase
buffer (50 mM Tris pH 8.0, 10% glycerol). The immunoprecipitates
were incubated at 37°C for 30 min with 1 unit per 10 µl reaction of calf
intestinal phosphatase (Boehringer Mannheim). Where indicated,
50 mM β-glycerophosphate was included in the reaction as a phos-
phatase inhibitor. 
Lucifer yellow uptake and actin localization
Lucifer yellow accumulation was performed as described [40]. Cells
were grown to log phase and concentrated ten-fold in fresh YPD con-
taining lucifer yellow (8 mg/ml) and incubated for 30 min at 30°C.
Stained cells were examined at a magnification of 630× using a
charge-coupled device camera mounted on a Leica DM-LB micro-
scope. Images were analyzed by using a Northern Exposure Image
System (Empix Imaging). For actin localization, 15 ml of cells were
grown in either YPD or YPDS (3% NaCl) to mid-log phase, and fixed
by addition of 37% formaldehyde to the media to a final concentration
of 4% for 20 min. Cells were harvested, resuspended in 1 ml PBS con-
taining 4% formaldehyde, and mixed for 1 h at room temperature
before washing four times with 1 ml PBS. Cells were resuspended in
PBS and briefly sonicated, then 50–75 µl of the fixed cells were
stained with 1/10 volume of rhodamine–phalloidin (Molecular Probes,
6.6 µM in MeOH) for 1 h at room temperature. Cells were washed five
times with 1 ml PBS and resuspended in 30 µl Pro-Long antifade
reagent (Molecular Probes); 5 µl of each preparation was spotted onto
a slide and a coverslip was placed on top of the slide for at least
15 min before viewing. Stained cells were photographed at 600× mag-
nification using Kodak TMAX400 film in a Nikon 35 mm camera
mounted on a Nikon Microphot-FXA fluorescence microscope.
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Supplementary material
A table of the yeast strains used in this study is published with this
paper on the internet.
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Table S1
Yeast strains used in this study.
Strain Genotype Reference or source
Y153 MATa trp1-901 leu2-3,-112, ura3-52 his3 ade2-101 gal4 gal80 URA3::GAL-lacZ LYS2::GAL-HIS3 [S1]
Y187 MATα trp1-901 leu2-3,-112, ura3-52 his3 ade2-101 gal4 gal80 URA3::GAL-lacZ [S2]
PJ69-4A MATa trp1-901 leu2-3,112 ura3-52 his3-200 gal4∆ gal80∆ LYS2::GAL1-HIS2 GAL2-ADE2 met2::GAL7-lacZ [S3]
BY261 MATa GAL2+ TRP+ ura3-52 lys2-801a ade2-107o his3∆200 leu2-∆1 This study
BY262 MATa/α GAL2+/gal2 TRP+ ura3-52/ura3-52 lys2-801a/lys2-801a ade2-107o/ ade2-107o This study
his3∆ 200/ his3∆ 200 leu2-∆1/leu2-∆1
BY263* MATa trp1∆63 [S4]
BY391 MATa pho85∆LEU2 trp1∆63 [S4]
BY344 MATa pcl2∆URA3 trp1∆63 This study
BY508 MATa rvs167∆TRP1 This study
BY559† MATa/α pho85∆LEU2/ pho85∆LEU2 trp1∆63/trp1∆63 [S4]
BY561 MATa/α rvs167∆TRP1/ rvs167∆TRP1 ADE+/ ade2-107o This study
BY637 MATa pcl1∆LEU2 pcl2∆LYS2 clg1∆URA3 pcl5∆TRP1 [S4]
BY697 MATa pcl2∆LYS2 pcl9∆HIS3 trp1∆63 This study
BY714 MATa pcl1∆LEU2 pcl2∆LYS2 clg1∆URA3 pcl5∆TRP1 pcl9∆HIS3 [S4]
BY867 MATa pho85∆TRP1 This study
BY730 MATa/α pcl1∆LEU2/ pcl1∆LEU pcl2∆LYS2/ pcl2∆LYS2 clg1∆URA3/ clg1∆URA3 [S4]
pcl5∆TRP1/ pcl5∆TRP1 pcl9∆HIS3/ pcl9∆HIS3
BY731 MATa/α pcl1∆LEU2/pcl1∆LEU2 pcl2∆LYS2/pcl2∆LYS2 clg1∆URA3/clg1∆URA3 pcl5∆TRP/pcl5∆TRP [S4]
*This strain and all following haploid strains are isogenic to BY261 with exceptions noted. †This strain and all following diploid strains are isogenic
to BY262 with exceptions noted.
